Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers;A lizofoszfátsav mint potenciális célpont az ováriumtumorok molekuláris diagnózisában és kezelésében

Orvosi Hetilap

Volumn 150, Issue 24, 2009, Pages 1109-1118

  Tanyi, János ^a   Rigó Jr , János ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Apoptosis; Lysophophatidic acid; Ovarian cancer; Treatment

Indexed keywords

AUTOTAXIN; BETA CATENIN; LIPID PHOSPHATE PHOSPHATASE 1A; LIPID PHOSPHATE PHOSPHATASE 2; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; PHOSPHATASE; PHOSPHATIDATE PHOSPHATASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; UNCLASSIFIED DRUG;

ARTICLE; BYSTANDER EFFECT; CANCER MORTALITY; CARCINOGENESIS; DNA MICROARRAY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR THERAPY; NUCLEOTIDE SEQUENCE; OVARY CANCER;

CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649992689     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28631     Document Type: Article

References (47)

1. Penson, R. T., Shannon, N. E., Seiden, M. V.: Ovarian cancer: an update of genetics and therapy. Compr. Ther., 1998, 24, 477-487.
2. Gray, J. W., Suzuki, S., Kuo, W. L. és mtsai: Genome copy number abnormalities in ovarian cancer. Gynecological Oncology Supplement (Suppl), 2003, 88, S16-S21.
3. Suzuki, S., Moore, D. H., Ginzinger, D. G. és mtsai: An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res., 2000, 60, 5382-5385.
4. Tanyi, J., Tory, K., Amo-Takyi, B. és mtsai: Frequent loss of chromosome 12 in human epithelial ovarian tumors: A chromosomal in situ hybridization study. Int. J. Gynecol. Pathol., 1998, 17, 106-112.
5. Tanyi, J., Rigó, J. Jr., Csapó, Z. és mtsa: Trisomy 12 in juvenile granulosa cell tumor of ovary during pregnancy: a report of two cases. J. Reprod. Med., 1999, 44, 826-832.
6. Tanyi, J., Páy, A., Rigó J. Jr. és mtsa: The mutation analysis of beta-catenin gene in epithelial carcinomas of the ovary. Orv. Hetil., 2000, 141, 1115-1119.
7. Eder, A. M., Sasagawa, T., Mao, M. és mtsai: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res., 2000, 6, 2482-2491.
8. Mills, G. B., May, C., McGill, M. és mtsai: A putative new growth factor in Ascetic fl uid from ovarian cancer patients: Identifi cation, characterization and mechanism of action. Cancer Res., 1988, 48, 1066-1071.
9. Van Corven, E. J., Van Rijswijk, A., Jalink, K. és mtsai: Mitogenic action of lysophosphatidic acid and phosphatidic acid on fi broblasts. Biochem. J., 1992, 281, 163-169.
10. Fang, X., Gaudette, D., Furui, T. és mtsai: Lysophospholipid growth factor in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad. Sci., 2000, 905, 188-208.
11. Mills, G. B., Moolenar, W. H.: The emerging role of lysophosphatidic acid in cancer. Nat. Rev., 2003, 3, 582-591.
12. Xiao, Y. J., Schwartz, B., Washington, M. és mtsai: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fl uids: comparison of the lysophospholipid contents in malignant vs. nonmalignant ascitic fl uids. Anal. Biochem., 2001, 290, 302-313.
13. Xu, Y., Gaudette, D., Boynton, J. D. és mtsai: Characterization of an ovarian cancer activating factor (OCAF) in ascites from ovarian cancer patients. Clin. Cancer Res., 1995, 1, 1223-1232.
14. Moolenaar, W., Jalink, K., Van Corven, E.: Lysophosphatidic acid: A bioactive phospholipids with growth factor-like properties. Rev. Physiol. Biochem. Pharmacol., 1992, 119, 7-65.
15. Xu, Y., Shen, Z., Wiper, D. W.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancer. JAMA, 1998, 280, 719-723.
16. Nakano, T., Raines, E. W., Abraham, J. A.: Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc. Natl. Acad. Sci. USA, 1994, 91, 1069-1073.
17. Pustilnik, T. B., Esterella, V., Wiener, J. és mtsai: Lysophosphatidic acid induces urokinase secretion in ovarian cancer cells. Clin. Cancer Res., 1999, 5, 3704-3710.
18. Schmidt, A., Wolde, M., Thiele, C. és mtsai: Endophillin I mediate synaptic vesicle formation by transfer of arachidonate to lyso-phosphatidic acid. Nature, 1999, 401, 133-141.
19. Umezu-Goto, M., Tanyi, J. L., Lahad, J. és mtsai: Lysophospha-tidic acid production and action: Validated targets in cancer. J. Cell. Biochem., 2004, 92, 1115-1140.
20. Goetzl, E. J., An, S.: Diversity of cellular receptors and functions for the lysophospholipid growth factor lysophosphatidic acid and sphingosine 1-phosphate. FASEB J., 1998, 12, 1589-1598.
21. Sano, T., Baker, D., Virág, T. és mtsai: Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem., 2002, 277, 21197-21206.
22. Aoki, J., Taira, A., Takanezawa, Y. és mtsai: Serum lysophosphatidic acid is produced through diverse phospholipasepathways. J. Biol. Chem., 2002, 277, 48737-48744.
23. Umezu-Goto, M., Kishi, Y., Taira, A. és mtsai: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol., 2002, 158, 227-233.
24. Tanyi, J. L., Crotzer, D., Wolf, J. és mtsai: Functional lipidomics: lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer. Functional Lipidomics. CRC Press/ Taylor & Francis, New York, 2006, 101-123.
25. Hu, Y. L., Tee, M. K., Goeztl, E. J. és mtsai: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst., 2001, 93, 762-768.
26. Brindley, D., Waggoner, D.: Mammalian lipid phosphate phosphohydrolases. J. Biol. Chem., 1998, 273, 24281-24284.
27. Kai, M., Wada, I., Imai, S. és mtsai: Identifi cation and cDNA cloning of 35 KDa phosphatidic acid phosphatase (type 2) bound to plasma membranes. Polymerase chain reaction amplifi cation of mouse H2O2-inducible hic53 clone yielded the cDNA encod- ing phosphatidic acid phosphatase. J. Biol. Chem., 1996, 271, 18931-18938.
28. Kai, M., Wada, I., Imai, S. és mtsai: Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase. J. Biol. Chem., 1997, 272, 24572-24578.
29. Alderton, F., Darroch, P., Sambi, B. és mtsai: G protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a and 2 in human embryonic kidney 293 cells. J. Biol. Chem., 2001, 276, 13452-13460.
30. An, S., Dickens, M. A., Bleu, T. és mtsai: Molecular cloning of human Edg 2 protein and its identifi cation as a functional cellular receptor for lysophosphatidic acid. Biochem. Byophis. Res. Commun., 1997, 231, 619-622.
31. An, S., Goetzl, E. J., Lee, H.: Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J. Cell Biochem., 1998, 30/31, 147-157.
32. Bandoh, K., Aoki, J., Hosomo, H. és mtsai: Molecular cloning and characterization of a novel human G-protein-coupled receptor, Edg-7, for lysophosphatidic acid. J Biol. Chem., 1999, 274, 27776-27785.
33. Xu, Y., Xiao, Y. J., Zhu, K. és mtsai: Unfolding the pathophysiological role of bioactive lysophospholipids. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2003, 3, 23-32.
34. Fang, X., Yu, S., Bast, R. C. és mtsai: Mechanisms of lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem., 2004, 279, 9653-9661.
35. Luquain, C., Singh, A., Wang, L. és mtsai: Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. J. Lipid. Res., 2003, 44, 1963-1975.
36. Tanyi, J. L., Hasegawa, J., LaPushin, R. és mtsai: Role of decreased level of LPP-1 in accumulation of lysophosphatidic acid (LPA) in ovarian cancer. Clin. Cancer Res., 2003, 9, 3534-3545.
37. Tanyi, J. L., Morris, A. J., Wolf, J. K. és mtsai: The human lipid phosphate phosphatase-3 decreases the growth, survival and tumorigenesis of ovarian cancer cells: validation of the lysophos-phatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res., 2003, 63, 1073-1082.
38. Hasegawa, Y., Erickson, J. R., Goddard, G. J. és mtsai: Identifi cation of phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J. Biol. Chem., 2003, 278, 11962-11969.
39. Kim, E. K., Yun, S. J., Do, K. H. és mtsai: Lysophosphatidic acid induces cell migration through the selective activation of Akt1. Exp. Mol. Med., 2008, 40, 445-452.
40. Hasegawa, Z., Murph, M., Zu, S. és mtsai: Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Mol. Oncol., 2008, 2, 54-69.
41. Tokumura, A., Majima, E., Kariya, Y. és mtsai: Identifi cation of human plasma lysophospholipase D, a lysophosphatidic acidproducing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem., 2002, 277, 39436-39442.
42. Saunders, L. P., Ouellette, A., Bandle, R. és mtsai: Identifi cation of small molecule inhibitors of autotoxin that inhibit melanoma cell migration and invasion. Mol. Cancer Ther, 2008, 10, 3352-3362.
43. Mills, G. B., Eder, A., Fang, X. és mtsai: Critical role of lysophospholipids in the pathophysiology, diagnosis and management of ovarian cancer. Cancer Treat. Res., 2002, 107, 259-283.
44. Van Leeuwen, F. N., Giepmans, B. N., van Meeteren, L. A. és mtsai: Lysophosphatidic acid: mitogen and motility factor. Biochem. Soc. Trans., 2003, 31, 1209-1212.
45. Stahle, M., Veit, C., Bachfi scher, U. és mtsai: Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J. Cell Sci., 2003, 116, 3835-3846.
46. Fishman, D. A., Liu, Y., Ellerbroek, S. M. és mtsai: Lysophospha-tidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res., 2001, 61, 3194-3199.
47. Gou, R., Kasbohm, E. A., Arora, P. és mtsai: Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology, 2006, 147, 4883-4892.